LYVE1 and neoplasm: 2.2. Infigratinib Acts Synergistically with Bevacizumab to Inhibit Tumor Growth, Cell Invasion, Hypoxia, and LYVE-1+ Peritumoral Lymphatic Vessels in an HCC13-0109 Orthotopic Model